Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. (PSTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PSTX · as of Dec 31, 2024
Ownership Breakdown
123
Institutional Holders
▲ 24 vs Q3
$519.21M
Total Inst. Value
▲ $365.83M vs Q3
97.47M
Shares Outstanding
freeFloat 66.38%
54.09M
13F Shares Held
▲ 458,556 vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PSTX largest shareholders · institutional ownership
Q4 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC biological products, (no diagnostic substances) | 10.01M | 10.30% | 10.30% | $96.11B | Feb 13, 2025 | ▼ 4.56M |
PENTWATER CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 8.63M | 8.88% | 8.88% | $82.80B | Feb 14, 2025 | ▲ 2.65M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 5.63M | 5.80% | 5.80% | $54.06B | Feb 7, 2025 | ▲ 507.5K |
NOMURA HOLDINGS INC biological products, (no diagnostic substances) | 5.12M | 5.26% | 5.26% | $49.10B | Feb 14, 2025 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 3.83M | 3.95% | 3.95% | $36.81B | Feb 11, 2025 | ▲ 171.1K |
ALPINE ASSOCIATES MANAGEMENT INC. biological products, (no diagnostic substances) | 2.02M | 2.08% | 2.08% | $19.36B | Feb 7, 2025 | NEW |
BOXER CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.00M | 2.06% | 2.06% | $19.20B | Feb 14, 2025 | NEW |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.63M | 1.68% | 1.68% | $15.65B | Feb 12, 2025 | ▲ 12.6K |
STATE STREET CORP biological products, (no diagnostic substances) | 1.59M | 1.64% | 1.64% | $15.31B | Feb 14, 2025 | ▼ 116.0K |
AISLING CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 1.04M | 1.07% | 1.07% | $10.02B | Feb 12, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2024 vs prior quarter
Q4 2024
15
Increased
+4.27M shares19
New Positions
first time holders13
Decreased
−11.05M shares0
Sold Out
fully exitedNet shares change (top 50)
6.78M
+4.27M / −11.05M
Net new holders
+21
19 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PSTX insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
65
Sell transactions
0.00
Buy/Sell ratio
$19M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Malin Life Sciences Holdings Ltd 10 percent owner | Jan 8, 2025 | U-Tender | 11,835,673 | $0.00 | $1.2K | 0 | Form 4 ↗ |
Amado Rafael director | Jan 8, 2025 | D-Return | 55,200 | $2.76 | $152.4K | 0 | Form 4 ↗ |
Amado Rafael director | Jan 8, 2025 | D-Return | 27,350 | $2.81 | $76.9K | 0 | Form 4 ↗ |
Amado Rafael director | Jan 8, 2025 | U-Tender | 58,950 | $9.00 | $530.5K | 0 | Form 4 ↗ |
Corning Luke director | Jan 8, 2025 | D-Return | 27,350 | $2.81 | $76.9K | 0 | Form 4 ↗ |
Corning Luke director | Jan 8, 2025 | D-Return | 28,500 | $2.01 | $57.3K | 0 | Form 4 ↗ |
Corning Luke director | Jan 8, 2025 | D-Return | 27,350 | $2.47 | $67.6K | 0 | Form 4 ↗ |
Corning Luke director | Jan 8, 2025 | D-Return | 45,833 | $9.78 | $448.2K | 0 | Form 4 ↗ |
Corning Luke director | Jan 8, 2025 | U-Tender | 58,950 | $9.00 | $530.5K | 0 | Form 4 ↗ |
Schmid John P. director | Jan 8, 2025 | D-Return | 32,076 | $12.00 | $384.9K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Poseida Therapeutics, Inc. (PSTX) is primarily owned by institutional investors, who hold approximately 55.5% of total shares outstanding. Company insiders own approximately 33.62%, while retail and public investors account for the remaining 10.88%.
The largest institutional shareholder of Poseida Therapeutics, Inc. is FMR LLC, holding approximately 10.01 million shares — equal to 10.30% of outstanding shares — as of December 31, 2024.
A total of 123 institutional investors currently hold PSTX stock, with a combined institutional value of approximately $519,205,390 as of the most recent 13F filing period.
Frequently asked questions
PSTX ownershipPoseida Therapeutics, Inc. (PSTX) is primarily owned by institutional investors, who hold approximately 55.5% of shares. The largest shareholder is FMR LLC with a 10.30% stake. Company insiders hold 33.62%. Data sourced from SEC Form 13F as of December 31, 2024.